CN116083434A - 一种mcm5基因及其新用途 - Google Patents

一种mcm5基因及其新用途 Download PDF

Info

Publication number
CN116083434A
CN116083434A CN202111316179.8A CN202111316179A CN116083434A CN 116083434 A CN116083434 A CN 116083434A CN 202111316179 A CN202111316179 A CN 202111316179A CN 116083434 A CN116083434 A CN 116083434A
Authority
CN
China
Prior art keywords
gene
mcm5
cell
seq
immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111316179.8A
Other languages
English (en)
Inventor
黄四洲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Medical College
Original Assignee
Chengdu Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Medical College filed Critical Chengdu Medical College
Priority to CN202111316179.8A priority Critical patent/CN116083434A/zh
Publication of CN116083434A publication Critical patent/CN116083434A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明提供了一种mcm5基因及其新用途,属于医药技术领域。本发明提供的mcm5mRNA的序列如SEQ ID NO:3所示。本发明首次发现该mcm5mRNA能够有效逆转T细胞发育不良现象,促进T细胞发育,可以用于制备预防和/或治疗T细胞发育异常引起的免疫缺陷病的药物,应用前景广阔。

Description

一种mcm5基因及其新用途
技术领域
本发明属于医药技术领域,具体涉及一种mcm5基因及其新用途。
背景技术
免疫缺陷病是由于免疫系统先天性发育不良或继发性障碍,导致免疫功能低下,临床表现以反复感染为主的一类疾病。免疫缺陷病患者由于免疫功能低下,常由低致病力病原体引起反复感染,并且具有重症化和难治性等特点,严重者可导致死亡。
T细胞(又名T淋巴细胞)由一群功能不同的异质性淋巴细胞组成,来源于骨髓的多能干细胞。在人体胚胎期和初生期,骨髓中的一部分多能干细胞或前T细胞迁移到胸腺内,在胸腺激素的诱导下分化成熟,成为具有免疫活性的T细胞。然后再随血循环到周围淋巴器官,在各自既定的区域定居、繁殖。受抗原激活即分化增殖,产生效应细胞,行使其免疫功能。T细胞在免疫系统疾病的治疗中具有重要作用,在机体肿瘤、艾滋病和自身免疫性疾病的治疗以及器官移植排斥反应中具有十分重要的功能,对于维持机体免疫耐受和免疫应答稳态非常重要。
T细胞的分化发育是指来自骨髓的淋巴干细胞进入胸腺,在此分裂、增殖、发育,并从皮质迁移入髓质,成为成熟T细胞的过程。T细胞在胸腺内的发育过程中经历细胞受体(TCR)重排与表达、阳性选择和阴性选择3个主要事件:(1)TCR基因的重排和表达使T细胞获得识别抗原的能力。研究发现,重组激活基因(Rags)在V(D)J重组过程中发挥重要作用,V(D)J重组过程中发生的免疫球蛋白(Ig)基因和TCR基因的重排和重组是T淋巴细胞成熟过程中的必需阶段。重组激活基因Rag1和Rag2编码的Rag1和Rag2蛋白在成熟前T细胞发育成为成熟T细胞的过程中,通过识别Ig或TCR基因,并结合基因片段中的重组信号序列(RSS),启动V(D)J重组。Rag1和Rag2在淋巴细胞V(D)J重排过程中缺一不可,任意一个缺失都会导致T淋巴细胞发育中断,表现为严重的T细胞早期发育阻滞,进而不能产生成熟的T淋巴细胞。(2)阳性选择指5%的能识别异体抗原,对自身抗原无应答能力的胸腺细胞存活并发育成熟,从而使机体对自身抗原产生了免疫耐受性。(3)阴性选择指DP、SP、胸腺细胞识别自身肽而诱导凋亡,这一过程使95%的对自身免疫应答而不能识别异体抗原的胸腺细胞发生凋亡。由此可见,T细胞在胸腺内发育成熟,是维持机体免疫能力的关键。开发出能够有效促进T细胞发育,逆转T细胞发育不良的药物对治疗免疫缺陷病具有重要意义。
发明内容
本发明的目的在于提供一种新的mcm5基因和mRNA,以及其在制备预防和/或治疗免疫缺陷病的药物中的用途。
本发明提供了一种mRNA,其特征在于:它的序列如SEQ ID NO:3所示。
本发明还提供了一种基因,它包含如SEQ ID NO:2所示的序列。
进一步地,它的序列如SEQ ID NO:1所示。
本发明还提供了一种预防和/或治疗免疫缺陷病的药物,它是以上述的mRNA或上述的基因为活性成分,加上药学上可接受的载体制得的制剂。
进一步地,所述制剂为注射制剂。
本发明还提供了上述的mRNA或上述的基因在制备预防和/或治疗免疫缺陷病的药物中的用途。
进一步地,所述免疫缺陷病为T细胞免疫缺陷病。
进一步地,所述为T细胞免疫缺陷病为T细胞发育不良引起的免疫缺陷病。
进一步地,所述T细胞为表达Rag1基因的T细胞。
进一步地,所述免疫缺陷病为系统性红斑狼疮、白血病或淋巴瘤。
本发明首次发现序列如SEQ ID NO:3所示的mcm5 mRNA能够有效逆转T细胞发育不良现象,促进T细胞发育,可以用于制备预防和/或治疗T细胞发育异常引起的免疫缺陷病的药物,应用前景广阔。
利用本发明提供的mcm5基因,以基因编码的方式也能转录得到SEQ ID NO:3所示的mcm5 mRNA,因此,本发明提供的mcm5基因也能用于逆转T细胞发育不良现象,促进T细胞发育,可以用于制备预防和/或治疗T细胞发育异常引起的免疫缺陷病的药物。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1:Mcm5突变体构建及斑马鱼外部表型图。利用CRISPER/Cas9技术获得mcm5突变体的示意图,斑马鱼mcm5突变体基因外显子3位置上21个碱基对与另外的66个碱基对交换,并提前出现了终止密码子(A);(B)pcr鉴定胚胎的基因型;(C)正常胚胎及mcm5突变体的外部表型图;(D)原位杂交技术检测mcm5突变体的突变效率。
图2:mcm5基因突变对Rag1标记的T细胞的影响。
具体实施方式
为了更清楚地理解本发明,现参照以下实施例及附图进一步描述本发明。实施例仅用于解释而不以任何方式限制本发明。
实施例中未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件,或按照制造商建议的条件;实施例中所用到的各种化学试剂均可以商购获得。
本发明实施例采用的mcm5基因的序列如SEQ ID NO:1所示,其中mcm5基因的编码序列(Coding sequence,简称CDs)如SEQ ID NO:2所示,编码基因转录得到的mRNA的序列如SEQ ID NO:3所示。
ataattatagcaatatcttaatcgatcatcgacagcacttatcgaaactatttcttattattagtttattacaaggtgtacattcctgaatatttgcaagaatgtcgggatttgatgatccaggagtttattacagtgacagctttggtggaggagaaagcgtcggcgacgagggagtcgtgaaacggagccagatcaagaagaagttccgtgagtttctgaggcagttcagagtcggaaccgatcgcactggattcacctacaaatacagagatgagctcaagagacactatactttgggagagtattggatcgaggtggaaatggaggatttggccagttttgatgaagatctgtcagactgtctgtacaaacttccttctgagaacctgcctttgttggaggaggctgcgcaggaagtggctgatgaggtcacacgtcctcggccagtaggagaagagactgttcaagacatacaggtcatgctgaagagcgacgctcatccagcctccatccgcagtctgaagtcagagcaggtttcgcgtctggtgaagattcccgggatcatcatctcctctactgctgtgagggccaaagccaccagagtgtgtcttcagtgccgcggatgcagagcggtgatcagcaacatccctctgccaccggggctgcagggttacgctctgcctcgcaagtgcaacactgagcaggcagggcgtgtcaagtgccctgtggatccatatttcatcattccagaccggtgtgtgtgtgtggatttccagactcagcgtctgcaggaagctcctgatgccgttcctcatggagagatgccgagacacatgcagctctactgcgacagatacttgtgtgatcgtgtagtaccaggcaacagagtgacagtcatgggcatctactccatcaagaaggtggcgcagaccaaagccaaaggccgtgataagggaactggtgttggcattcgctcggcatatctgcgtgttgtcggcatcgatgtggacactgaaggagcaggccgtggtgccactggttcagtttctccccaagaagaagaggagttaagatctctggccgcttctccctctgtttatgactctctggctcgctctctcgccccgtccatctatggcagtgatgacctgaaaaaagctattgcctgcctgctgttcggcggctccaggaagaggttgcctgatggtctgacacgaagaggggatattaacctgctgatgctgggagatccaggcacagccaagtctcaactgctgaagtttgttgagagatgctctccaattggggtctacacctctggaaagggcagcagtgcagctggtttgaccgcctctgttcttcgggaccccaccactcgtggttttgtcatggagggaggcgctatggtgttagctgatggtggagttgtctgcatcgatgagtttgacaagatgagagaggatgatagagtcgcaatccatgaggccatggagcagcagaccatctctattgcaaaggctgggatcaccaccactctgaactcgcgctgctctgtattagctgccgccaactctgtgttcggtcgctgggatgatacaaagggagaggacaacattgacttcatgcccaccattctgtctcgattcgacatgatcttcatcatcaaagatcatcacgaccaacagcgagacatgactttggctcgacacgtgatgaatgttcacctgagcgctcaaacgcagacggagggggtcgagggagagattcctctggccacgttgaagaaatacatcgcctattctagagtaaaatgtggacctcgactgtctgcggcagctgcagagaagctgaagaacagatacgtgttgatgagaagcggagcgaaggagcatgagagagagactgacagacgagtgtccatccccatcactgtcaggcagctagaggccgtggtgcgcattgcagagtcacttgctaagatgaagctgcagcccattgctggagaagaagaggtggacgaggctctgagactcttccaggtgtccacgctggatgctgctctgtctggcagcctctccggtgttgaagggtttaccactcaggaggatcaggagatgatctcccgcatcgaaaaacagctgaagagacgcttcgccatcggctcgcaggtgtctgaacacagcatcatacaggacttcgccaaacagaaatatccagagcacgctattcaaaaggtcctttacctgatgttgaggagaggtgaactgcagcaccgcatgcagaggaaggtgctttacagggtcaaatagatgaacgctttgggtttacttcataaaagagtctggtgggtgtccaaatacataacagaaatgaaatacaactcagaattattgtacatagttgtctggacactttattgctggagatatgttctgtgtatcattcttgcttgttgttatagctttgtgtggtttaaagtatgttacgaatacaacagtatgctctactgtctactttcaatgaaaaaaaaaagtttaattaaaaatccactttgattgattgtcaaactaaagaatacagcctttttgtatgggaatttattaaagcagttaagaaacaaaaaaaaaaaaaaaaa(SEQ ID NO:1)。
atgtcgggatttgatgatccaggagtttattacagtgacagctttggtggaggagaaagcgtcggcgacgagggagtcgtgaaacggagccagatcaagaagaagttccgtgagtttctgaggcagttcagagtcggaaccgatcgcactggattcacctacaaatacagagatgagctcaagagacactatactttgggagagtattggatcgaggtggaaatggaggatttggccagttttgatgaagatctgtcagactgtctgtacaaacttccttctgagaacctgcctttgttggaggaggctgcgcaggaagtggctgatgaggtcacacgtcctcggccagtaggagaagagactgttcaagacatacaggtcatgctgaagagcgacgctcatccagcctccatccgcagtctgaagtcagagcaggtttcgcgtctggtgaagattcccgggatcatcatctcctctactgctgtgagggccaaagccaccagagtgtgtcttcagtgccgcggatgcagagcggtgatcagcaacatccctctgccaccggggctgcagggttacgctctgcctcgcaagtgcaacactgagcaggcagggcgtgtcaagtgccctgtggatccatatttcatcattccagaccggtgtgtgtgtgtggatttccagactcagcgtctgcaggaagctcctgatgccgttcctcatggagagatgccgagacacatgcagctctactgcgacagatacttgtgtgatcgtgtagtaccaggcaacagagtgacagtcatgggcatctactccatcaagaaggtggcgcagaccaaagccaaaggccgtgataagggaactggtgttggcattcgctcggcatatctgcgtgttgtcggcatcgatgtggacactgaaggagcaggccgtggtgccactggttcagtttctccccaagaagaagaggagttaagatctctggccgcttctccctctgtttatgactctctggctcgctctctcgccccgtccatctatggcagtgatgacctgaaaaaagctattgcctgcctgctgttcggcggctccaggaagaggttgcctgatggtctgacacgaagaggggatattaacctgctgatgctgggagatccaggcacagccaagtctcaactgctgaagtttgttgagagatgctctccaattggggtctacacctctggaaagggcagcagtgcagctggtttgaccgcctctgttcttcgggaccccaccactcgtggttttgtcatggagggaggcgctatggtgttagctgatggtggagttgtctgcatcgatgagtttgacaagatgagagaggatgatagagtcgcaatccatgaggccatggagcagcagaccatctctattgcaaaggctgggatcaccaccactctgaactcgcgctgctctgtattagctgccgccaactctgtgttcggtcgctgggatgatacaaagggagaggacaacattgacttcatgcccaccattctgtctcgattcgacatgatcttcatcatcaaagatcatcacgaccaacagcgagacatgactttggctcgacacgtgatgaatgttcacctgagcgctcaaacgcagacggagggggtcgagggagagattcctctggccacgttgaagaaatacatcgcctattctagagtaaaatgtggacctcgactgtctgcggcagctgcagagaagctgaagaacagatacgtgttgatgagaagcggagcgaaggagcatgagagagagactgacagacgagtgtccatccccatcactgtcaggcagctagaggccgtggtgcgcattgcagagtcacttgctaagatgaagctgcagcccattgctggagaagaagaggtggacgaggctctgagactcttccaggtgtccacgctggatgctgctctgtctggcagcctctccggtgttgaagggtttaccactcaggaggatcaggagatgatctcccgcatcgaaaaacagctgaagagacgcttcgccatcggctcgcaggtgtctgaacacagcatcatacaggacttcgccaaacagaaatatccagagcacgctattcaaaaggtcctttacctgatgttgaggagaggtgaactgcagcaccgcatgcagaggaaggtgctttacagggtcaaatag(SEQ ID NO:2)。
augucgggauuugaugauccaggaguuuauuacagugacagcuuugguggaggagaaagcgucggcgacgagggagucgugaaacggagccagaucaagaagaaguuccgugaguuucugaggcaguucagagucggaaccgaucgcacuggauucaccuacaaauacagagaugagcucaagagacacuauacuuugggagaguauuggaucgagguggaaauggaggauuuggccaguuuugaugaagaucugucagacugucuguacaaacuuccuucugagaaccugccuuuguuggaggaggcugcgcaggaaguggcugaugaggucacacguccucggccaguaggagaagagacuguucaagacauacaggucaugcugaagagcgacgcucauccagccuccauccgcagucugaagucagagcagguuucgcgucuggugaagauucccgggaucaucaucuccucuacugcugugagggccaaagccaccagagugugucuucagugccgcggaugcagagcggugaucagcaacaucccucugccaccggggcugcaggguuacgcucugccucgcaagugcaacacugagcaggcagggcgugucaagugcccuguggauccauauuucaucauuccagaccgguguguguguguggauuuccagacucagcgucugcaggaagcuccugaugccguuccucauggagagaugccgagacacaugcagcucuacugcgacagauacuugugugaucguguaguaccaggcaacagagugacagucaugggcaucuacuccaucaagaagguggcgcagaccaaagccaaaggccgugauaagggaacugguguuggcauucgcucggcauaucugcguguugucggcaucgauguggacacugaaggagcaggccguggugccacugguucaguuucuccccaagaagaagaggaguuaagaucucuggccgcuucucccucuguuuaugacucucuggcucgcucucucgccccguccaucuauggcagugaugaccugaaaaaagcuauugccugccugcuguucggcggcuccaggaagagguugccugauggucugacacgaagaggggauauuaaccugcugaugcugggagauccaggcacagccaagucucaacugcugaaguuuguugagagaugcucuccaauuggggucuacaccucuggaaagggcagcagugcagcugguuugaccgccucuguucuucgggaccccaccacucgugguuuugucauggagggaggcgcuaugguguuagcugaugguggaguugucugcaucgaugaguuugacaagaugagagaggaugauagagucgcaauccaugaggccauggagcagcagaccaucucuauugcaaaggcugggaucaccaccacucugaacucgcgcugcucuguauuagcugccgccaacucuguguucggucgcugggaugauacaaagggagaggacaacauugacuucaugcccaccauucugucucgauucgacaugaucuucaucaucaaagaucaucacgaccaacagcgagacaugacuuuggcucgacacgugaugaauguucaccugagcgcucaaacgcagacggagggggucgagggagagauuccucuggccacguugaagaaauacaucgccuauucuagaguaaaauguggaccucgacugucugcggcagcugcagagaagcugaagaacagauacguguugaugagaagcggagcgaaggagcaugagagagagacugacagacgaguguccauccccaucacugucaggcagcuagaggccguggugcgcauugcagagucacuugcuaagaugaagcugcagcccauugcuggagaagaagagguggacgaggcucugagacucuuccagguguccacgcuggaugcugcucugucuggcagccucuccgguguugaaggguuuaccacucaggaggaucaggagaugaucucccgcaucgaaaaacagcugaagagacgcuucgccaucggcucgcaggugucugaacacagcaucauacaggacuucgccaaacagaaauauccagagcacgcuauucaaaagguccuuuaccugauguugaggagaggugaacugcagcaccgcaugcagaggaaggugcuuuacagggucaaauag(SEQ ID NO:3)。
实施例1:mcm5 mRNA的制备
根据SEQ ID NO:3所示序列,合成mcm5 mRNA。
实施例2:mcm5 mRNA对T细胞发育的影响
1、实验方法
(1)斑马鱼mcm5突变体的构建
为研究mcm5功能缺失后是否影响T细胞的发育,本发明利用CRISPER/Cas9技术对mcm5基因序列进行编辑,并获得了mcm5基因的斑马鱼突变体。在该突变体中外显子3位置上的21个碱基对被另外的66个碱基对替换,从而导致了mcm5终止密码子的提前出现(图1A)。
由于mcm5是插入突变,本发明设计了特异性引物,PCR结果显示杂合子是两条带,纯合子是相较于野生型更长的一条带(图1B)。mcm5纯合子从第3天开始相比野生型表现出头部小,眼睛小的外部表型(图1C)。由于mcm5是一个母源性基因,在mcm5突变体受精后24hpf时期及以前还能检测到mcm5的少量表达,在受精后72hpf,mcm5在突变体中几乎不表达(图1D)。证明mcm5突变体构建成功。
(2)对斑马鱼mcm5突变体注射mcm5 mRNA
将mcm5 mRNA溶于灭菌水中,获得浓度为25ng/ul的mcm5 mRNA溶液。将mcm5 mRNA溶液于mcm5基因的斑马鱼突变体胚胎1-4细胞期注射到卵黄,每个胚胎注射一次,每次2nL。注射五天后,以T细胞特异性表达的Rag1基因为标记,观察斑马鱼的T细胞发育情况。
2、实验结果
从图2可以看出,斑马鱼mcm5突变体Rag1标记的T细胞大量丢失(约90%丢失)。但是,对斑马鱼mcm5突变体注射mcm5 mRNA 5天后,成功回救T细胞发育现象。
上述实验结果表明,mcm5 mRNA能够有效逆转T细胞发育不良现象,促进T细胞发育,能够用于制备预防和治疗T细胞发育不良引起的免疫缺陷病。
综上,本发明提供了一种mcm5 mRNA及其新用途。本发明首次发现该mcm5 mRNA能够有效逆转T细胞发育不良现象,促进T细胞发育,可以用于制备预防和/或治疗T细胞发育异常引起的免疫缺陷病的药物,应用前景广阔。
SEQUENCE LISTING
<110> 成都医学院
<120> 一种mcm5基因及其新用途
<130> GY044-2021P0114202CC
<160> 3
<170> PatentIn version 3.5
<210> 1
<211> 2638
<212> DNA
<213> 人工序列
<400> 1
ataattatag caatatctta atcgatcatc gacagcactt atcgaaacta tttcttatta 60
ttagtttatt acaaggtgta cattcctgaa tatttgcaag aatgtcggga tttgatgatc 120
caggagttta ttacagtgac agctttggtg gaggagaaag cgtcggcgac gagggagtcg 180
tgaaacggag ccagatcaag aagaagttcc gtgagtttct gaggcagttc agagtcggaa 240
ccgatcgcac tggattcacc tacaaataca gagatgagct caagagacac tatactttgg 300
gagagtattg gatcgaggtg gaaatggagg atttggccag ttttgatgaa gatctgtcag 360
actgtctgta caaacttcct tctgagaacc tgcctttgtt ggaggaggct gcgcaggaag 420
tggctgatga ggtcacacgt cctcggccag taggagaaga gactgttcaa gacatacagg 480
tcatgctgaa gagcgacgct catccagcct ccatccgcag tctgaagtca gagcaggttt 540
cgcgtctggt gaagattccc gggatcatca tctcctctac tgctgtgagg gccaaagcca 600
ccagagtgtg tcttcagtgc cgcggatgca gagcggtgat cagcaacatc cctctgccac 660
cggggctgca gggttacgct ctgcctcgca agtgcaacac tgagcaggca gggcgtgtca 720
agtgccctgt ggatccatat ttcatcattc cagaccggtg tgtgtgtgtg gatttccaga 780
ctcagcgtct gcaggaagct cctgatgccg ttcctcatgg agagatgccg agacacatgc 840
agctctactg cgacagatac ttgtgtgatc gtgtagtacc aggcaacaga gtgacagtca 900
tgggcatcta ctccatcaag aaggtggcgc agaccaaagc caaaggccgt gataagggaa 960
ctggtgttgg cattcgctcg gcatatctgc gtgttgtcgg catcgatgtg gacactgaag 1020
gagcaggccg tggtgccact ggttcagttt ctccccaaga agaagaggag ttaagatctc 1080
tggccgcttc tccctctgtt tatgactctc tggctcgctc tctcgccccg tccatctatg 1140
gcagtgatga cctgaaaaaa gctattgcct gcctgctgtt cggcggctcc aggaagaggt 1200
tgcctgatgg tctgacacga agaggggata ttaacctgct gatgctggga gatccaggca 1260
cagccaagtc tcaactgctg aagtttgttg agagatgctc tccaattggg gtctacacct 1320
ctggaaaggg cagcagtgca gctggtttga ccgcctctgt tcttcgggac cccaccactc 1380
gtggttttgt catggaggga ggcgctatgg tgttagctga tggtggagtt gtctgcatcg 1440
atgagtttga caagatgaga gaggatgata gagtcgcaat ccatgaggcc atggagcagc 1500
agaccatctc tattgcaaag gctgggatca ccaccactct gaactcgcgc tgctctgtat 1560
tagctgccgc caactctgtg ttcggtcgct gggatgatac aaagggagag gacaacattg 1620
acttcatgcc caccattctg tctcgattcg acatgatctt catcatcaaa gatcatcacg 1680
accaacagcg agacatgact ttggctcgac acgtgatgaa tgttcacctg agcgctcaaa 1740
cgcagacgga gggggtcgag ggagagattc ctctggccac gttgaagaaa tacatcgcct 1800
attctagagt aaaatgtgga cctcgactgt ctgcggcagc tgcagagaag ctgaagaaca 1860
gatacgtgtt gatgagaagc ggagcgaagg agcatgagag agagactgac agacgagtgt 1920
ccatccccat cactgtcagg cagctagagg ccgtggtgcg cattgcagag tcacttgcta 1980
agatgaagct gcagcccatt gctggagaag aagaggtgga cgaggctctg agactcttcc 2040
aggtgtccac gctggatgct gctctgtctg gcagcctctc cggtgttgaa gggtttacca 2100
ctcaggagga tcaggagatg atctcccgca tcgaaaaaca gctgaagaga cgcttcgcca 2160
tcggctcgca ggtgtctgaa cacagcatca tacaggactt cgccaaacag aaatatccag 2220
agcacgctat tcaaaaggtc ctttacctga tgttgaggag aggtgaactg cagcaccgca 2280
tgcagaggaa ggtgctttac agggtcaaat agatgaacgc tttgggttta cttcataaaa 2340
gagtctggtg ggtgtccaaa tacataacag aaatgaaata caactcagaa ttattgtaca 2400
tagttgtctg gacactttat tgctggagat atgttctgtg tatcattctt gcttgttgtt 2460
atagctttgt gtggtttaaa gtatgttacg aatacaacag tatgctctac tgtctacttt 2520
caatgaaaaa aaaaagttta attaaaaatc cactttgatt gattgtcaaa ctaaagaata 2580
cagccttttt gtatgggaat ttattaaagc agttaagaaa caaaaaaaaa aaaaaaaa 2638
<210> 2
<211> 2211
<212> DNA
<213> 人工序列
<400> 2
atgtcgggat ttgatgatcc aggagtttat tacagtgaca gctttggtgg aggagaaagc 60
gtcggcgacg agggagtcgt gaaacggagc cagatcaaga agaagttccg tgagtttctg 120
aggcagttca gagtcggaac cgatcgcact ggattcacct acaaatacag agatgagctc 180
aagagacact atactttggg agagtattgg atcgaggtgg aaatggagga tttggccagt 240
tttgatgaag atctgtcaga ctgtctgtac aaacttcctt ctgagaacct gcctttgttg 300
gaggaggctg cgcaggaagt ggctgatgag gtcacacgtc ctcggccagt aggagaagag 360
actgttcaag acatacaggt catgctgaag agcgacgctc atccagcctc catccgcagt 420
ctgaagtcag agcaggtttc gcgtctggtg aagattcccg ggatcatcat ctcctctact 480
gctgtgaggg ccaaagccac cagagtgtgt cttcagtgcc gcggatgcag agcggtgatc 540
agcaacatcc ctctgccacc ggggctgcag ggttacgctc tgcctcgcaa gtgcaacact 600
gagcaggcag ggcgtgtcaa gtgccctgtg gatccatatt tcatcattcc agaccggtgt 660
gtgtgtgtgg atttccagac tcagcgtctg caggaagctc ctgatgccgt tcctcatgga 720
gagatgccga gacacatgca gctctactgc gacagatact tgtgtgatcg tgtagtacca 780
ggcaacagag tgacagtcat gggcatctac tccatcaaga aggtggcgca gaccaaagcc 840
aaaggccgtg ataagggaac tggtgttggc attcgctcgg catatctgcg tgttgtcggc 900
atcgatgtgg acactgaagg agcaggccgt ggtgccactg gttcagtttc tccccaagaa 960
gaagaggagt taagatctct ggccgcttct ccctctgttt atgactctct ggctcgctct 1020
ctcgccccgt ccatctatgg cagtgatgac ctgaaaaaag ctattgcctg cctgctgttc 1080
ggcggctcca ggaagaggtt gcctgatggt ctgacacgaa gaggggatat taacctgctg 1140
atgctgggag atccaggcac agccaagtct caactgctga agtttgttga gagatgctct 1200
ccaattgggg tctacacctc tggaaagggc agcagtgcag ctggtttgac cgcctctgtt 1260
cttcgggacc ccaccactcg tggttttgtc atggagggag gcgctatggt gttagctgat 1320
ggtggagttg tctgcatcga tgagtttgac aagatgagag aggatgatag agtcgcaatc 1380
catgaggcca tggagcagca gaccatctct attgcaaagg ctgggatcac caccactctg 1440
aactcgcgct gctctgtatt agctgccgcc aactctgtgt tcggtcgctg ggatgataca 1500
aagggagagg acaacattga cttcatgccc accattctgt ctcgattcga catgatcttc 1560
atcatcaaag atcatcacga ccaacagcga gacatgactt tggctcgaca cgtgatgaat 1620
gttcacctga gcgctcaaac gcagacggag ggggtcgagg gagagattcc tctggccacg 1680
ttgaagaaat acatcgccta ttctagagta aaatgtggac ctcgactgtc tgcggcagct 1740
gcagagaagc tgaagaacag atacgtgttg atgagaagcg gagcgaagga gcatgagaga 1800
gagactgaca gacgagtgtc catccccatc actgtcaggc agctagaggc cgtggtgcgc 1860
attgcagagt cacttgctaa gatgaagctg cagcccattg ctggagaaga agaggtggac 1920
gaggctctga gactcttcca ggtgtccacg ctggatgctg ctctgtctgg cagcctctcc 1980
ggtgttgaag ggtttaccac tcaggaggat caggagatga tctcccgcat cgaaaaacag 2040
ctgaagagac gcttcgccat cggctcgcag gtgtctgaac acagcatcat acaggacttc 2100
gccaaacaga aatatccaga gcacgctatt caaaaggtcc tttacctgat gttgaggaga 2160
ggtgaactgc agcaccgcat gcagaggaag gtgctttaca gggtcaaata g 2211
<210> 3
<211> 2211
<212> RNA
<213> 人工序列
<400> 3
augucgggau uugaugaucc aggaguuuau uacagugaca gcuuuggugg aggagaaagc 60
gucggcgacg agggagucgu gaaacggagc cagaucaaga agaaguuccg ugaguuucug 120
aggcaguuca gagucggaac cgaucgcacu ggauucaccu acaaauacag agaugagcuc 180
aagagacacu auacuuuggg agaguauugg aucgaggugg aaauggagga uuuggccagu 240
uuugaugaag aucugucaga cugucuguac aaacuuccuu cugagaaccu gccuuuguug 300
gaggaggcug cgcaggaagu ggcugaugag gucacacguc cucggccagu aggagaagag 360
acuguucaag acauacaggu caugcugaag agcgacgcuc auccagccuc cauccgcagu 420
cugaagucag agcagguuuc gcgucuggug aagauucccg ggaucaucau cuccucuacu 480
gcugugaggg ccaaagccac cagagugugu cuucagugcc gcggaugcag agcggugauc 540
agcaacaucc cucugccacc ggggcugcag gguuacgcuc ugccucgcaa gugcaacacu 600
gagcaggcag ggcgugucaa gugcccugug gauccauauu ucaucauucc agaccggugu 660
gugugugugg auuuccagac ucagcgucug caggaagcuc cugaugccgu uccucaugga 720
gagaugccga gacacaugca gcucuacugc gacagauacu ugugugaucg uguaguacca 780
ggcaacagag ugacagucau gggcaucuac uccaucaaga agguggcgca gaccaaagcc 840
aaaggccgug auaagggaac ugguguuggc auucgcucgg cauaucugcg uguugucggc 900
aucgaugugg acacugaagg agcaggccgu ggugccacug guucaguuuc uccccaagaa 960
gaagaggagu uaagaucucu ggccgcuucu cccucuguuu augacucucu ggcucgcucu 1020
cucgccccgu ccaucuaugg cagugaugac cugaaaaaag cuauugccug ccugcuguuc 1080
ggcggcucca ggaagagguu gccugauggu cugacacgaa gaggggauau uaaccugcug 1140
augcugggag auccaggcac agccaagucu caacugcuga aguuuguuga gagaugcucu 1200
ccaauugggg ucuacaccuc uggaaagggc agcagugcag cugguuugac cgccucuguu 1260
cuucgggacc ccaccacucg ugguuuuguc auggagggag gcgcuauggu guuagcugau 1320
gguggaguug ucugcaucga ugaguuugac aagaugagag aggaugauag agucgcaauc 1380
caugaggcca uggagcagca gaccaucucu auugcaaagg cugggaucac caccacucug 1440
aacucgcgcu gcucuguauu agcugccgcc aacucugugu ucggucgcug ggaugauaca 1500
aagggagagg acaacauuga cuucaugccc accauucugu cucgauucga caugaucuuc 1560
aucaucaaag aucaucacga ccaacagcga gacaugacuu uggcucgaca cgugaugaau 1620
guucaccuga gcgcucaaac gcagacggag ggggucgagg gagagauucc ucuggccacg 1680
uugaagaaau acaucgccua uucuagagua aaauguggac cucgacuguc ugcggcagcu 1740
gcagagaagc ugaagaacag auacguguug augagaagcg gagcgaagga gcaugagaga 1800
gagacugaca gacgaguguc cauccccauc acugucaggc agcuagaggc cguggugcgc 1860
auugcagagu cacuugcuaa gaugaagcug cagcccauug cuggagaaga agagguggac 1920
gaggcucuga gacucuucca gguguccacg cuggaugcug cucugucugg cagccucucc 1980
gguguugaag gguuuaccac ucaggaggau caggagauga ucucccgcau cgaaaaacag 2040
cugaagagac gcuucgccau cggcucgcag gugucugaac acagcaucau acaggacuuc 2100
gccaaacaga aauauccaga gcacgcuauu caaaaggucc uuuaccugau guugaggaga 2160
ggugaacugc agcaccgcau gcagaggaag gugcuuuaca gggucaaaua g 2211

Claims (10)

1.一种mRNA,其特征在于:它的序列如SEQ ID NO:3所示。
2.一种基因,其特征在于:它包含如SEQ ID NO:2所示的序列。
3.根据权利要求2所述的基因,其特征在于:它的序列如SEQ ID NO:1所示。
4.一种预防和/或治疗免疫缺陷病的药物,其特征在于:它是以权利要求1所述的mRNA或权利要求2~3任一项所述的基因为活性成分,加上药学上可接受的载体制得的制剂。
5.根据权利要求4所述的药物,其特征在于:所述制剂为注射制剂。
6.权利要求1所述的mRNA或权利要求2~3任一项所述的基因在制备预防和/或治疗免疫缺陷病的药物中的用途。
7.根据权利要求6所述的用途,其特征在于:所述免疫缺陷病为T细胞免疫缺陷病。
8.根据权利要求7所述的用途,其特征在于:所述为T细胞免疫缺陷病为T细胞发育不良引起的免疫缺陷病。
9.根据权利要求8所述的用途,其特征在于:所述T细胞为表达Rag1基因的T细胞。
10.根据权利要求6所述的用途,其特征在于:所述免疫缺陷病为系统性红斑狼疮、白血病或淋巴瘤。
CN202111316179.8A 2021-11-08 2021-11-08 一种mcm5基因及其新用途 Pending CN116083434A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111316179.8A CN116083434A (zh) 2021-11-08 2021-11-08 一种mcm5基因及其新用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111316179.8A CN116083434A (zh) 2021-11-08 2021-11-08 一种mcm5基因及其新用途

Publications (1)

Publication Number Publication Date
CN116083434A true CN116083434A (zh) 2023-05-09

Family

ID=86205091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111316179.8A Pending CN116083434A (zh) 2021-11-08 2021-11-08 一种mcm5基因及其新用途

Country Status (1)

Country Link
CN (1) CN116083434A (zh)

Similar Documents

Publication Publication Date Title
Domen et al. Self-renewal, differentiation or death: regulation and manipulation of hematopoietic stem cell fate
JP3333902B2 (ja) 遺伝子導入動物、それから得られる細胞および細胞系、およびその使用
Ernst et al. Functional and biochemical association of Hck with the LIF/IL‐6 receptor signal transducing subunit gp130 in embryonic stem cells.
Acampora et al. Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene Dlx5
Broun et al. Cngsc, a homologue of goosecoid, participates in the patterning of the head, and is expressed in the organizer region of Hydra
US8101412B2 (en) Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
US6210960B1 (en) Nucleic acid encoding a transcription factor, IDX-1
Vieux‐Rochas et al. Spatio‐temporal dynamics of gene expression of the Edn1‐Dlx5/6 pathway during development of the lower jaw
US20220323503A1 (en) Methods and compositions for reconstituting microglia
US7932352B2 (en) Semaphorin genes (I)
JPH10500842A (ja) ユビキチン結合酵素をコードするdna
KR102074336B1 (ko) 뇌유래-신경영양인자를 발현하는 중간엽줄기세포주 및 이의 용도
CN112839709A (zh) 治疗神经退行性疾病的神经干细胞组合物和方法
CA3148895A1 (en) Treatment of chronic granulomatous disease
CN108070613A (zh) 人源化基因改造动物模型的制备方法及应用
CN116083434A (zh) 一种mcm5基因及其新用途
JP2012050431A (ja) Blimp1およびレポーター分子を共発現する改変細胞およびその使用方法
KR101658135B1 (ko) 혈액 응고인자 ⅷ 유전자를 타겟으로 하는 엔도뉴클레아제 및 이의 용도
JP3410738B2 (ja) ミクログリアからなる医薬用キャリアー
JP2004519437A (ja) 移植寛容を増進させ、損傷組織を治療する為の胚性幹細胞由来細胞の利用
WO2021190226A1 (zh) 单碱基编辑介导的剪接修复在制备治疗脊髓性肌萎缩症中的应用
JP4387108B2 (ja) 株化ミクログリア
CN112236159B (zh) Oca-b肽缀合物和治疗方法
Shangaris Can we treat congenital blood disorders by transplantation of stem cells, gene therapy to the fetus?
O'Malley Discerning the role of PU. 1 and GFP in adult hematopoietic stem cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination